March 2017, Vol. 6, No. 1

The Road MAP to Targeted Therapy in Squamous-Cell Carcinoma: Lung Cancer Master Protocol (SWOG S1400) Overview

Lung cancer is the leading cause of cancer-related death worldwide. More than 85% of cases of the disease are classified as non–small-cell lung cancer (NSCLC), with a predicted 5-year survival rate of 16%.1 The battle against lung cancer entered a new era with the identification of actionable genomic aberrations in [ Read More ]

Yasir Y. Elamin, MD, Medical Oncology Fellow, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Lung Cancer

Follicular Lymphoma: An Overview of Current Treatments and Unmet Patient Needs

Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL) after diffuse large B-cell lymphoma (DLBCL), with an estimated 16,000 new cases diagnosed annually in the United States.1,2 However, unlike DLBCL, which is a histologically aggressive lymphoma, FL has a long natural history, with 15% to 20% [ Read More ]

Follicular Lymphoma

Talimogene Laherparepvec (T-VEC) as Cancer Immunotherapy

Dr Kaufman is the Chief Surgical Officer and Associate Director for Clinical Science at Rutgers Cancer Institute of New Jersey. He is a leading authority on tumor immunotherapy for the treatment of melanoma and has published more than 400 peer-reviewed scientific papers, books, review articles, and abstracts. He serves on [ Read More ]

Sachin Jhawar, MD, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Sharad Goyal, MD, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Praveen K. Bommareddy, MS, Department of Surgery, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Andrew Zloza, MD, PhD, Division of Surgical Oncology Research, Section of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Howard L. Kaufman, MD, FACS, Department of Surgery, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Melanoma

Personalized Care in Colorectal Cancer: Tailoring Treatment and Healthcare Delivery

In the United States, colorectal cancer (CRC) is the fourth most common malignancy, with 134,490 new cases and 49,190 deaths estimated in 2016.1 Among these patients, 25% present with advanced disease at diagnosis, and nearly 50% will eventually develop metastatic disease.2 Survival rates for metastatic CRC (mCRC) have been improving, [ Read More ]

Sheetal Kircher, MD, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
Halla Nimeiri, MD, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
Julia Trosman, PhD, MBA, Northwestern University, Chicago, IL
Christine Weldon, MBA, Northwestern University, Chicago, IL
Al B. Benson III, MD, FACP, FASCO, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
Colorectal Cancer